LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:LGND • US53220K5048

198.33 USD
-0.51 (-0.26%)
At close: Feb 4, 2026
197.36 USD
-0.97 (-0.49%)
Pre-Market: 2/5/2026, 8:44:34 AM
Fundamental Rating

6

LGND gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While LGND has a great profitability rating, there are some minor concerns on its financial health. LGND is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make LGND a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year LGND was profitable.
  • LGND had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
  • In the past 5 years LGND always reported a positive cash flow from operatings.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 3.29%, LGND belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
  • LGND has a better Return On Equity (5.11%) than 83.25% of its industry peers.
  • LGND has a Return On Invested Capital of 1.58%. This is in the better half of the industry: LGND outperforms 78.53% of its industry peers.
  • LGND had an Average Return On Invested Capital over the past 3 years of 1.12%. This is significantly below the industry average of 12.83%.
  • The last Return On Invested Capital (1.58%) for LGND is above the 3 year average (1.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROIC 1.58%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

  • LGND has a better Profit Margin (19.34%) than 90.58% of its industry peers.
  • Looking at the Operating Margin, with a value of 11.48%, LGND belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
  • LGND's Operating Margin has declined in the last couple of years.
  • The Gross Margin of LGND (94.27%) is better than 96.34% of its industry peers.
  • LGND's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • LGND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, LGND has more shares outstanding
  • LGND has more shares outstanding than it did 5 years ago.
  • LGND has a worse debt/assets ratio than last year.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that LGND is not in any danger for bankruptcy at the moment.
  • LGND's Altman-Z score of 5.82 is fine compared to the rest of the industry. LGND outperforms 76.44% of its industry peers.
  • The Debt to FCF ratio of LGND is 14.48, which is on the high side as it means it would take LGND, 14.48 years of fcf income to pay off all of its debts.
  • LGND has a Debt to FCF ratio of 14.48. This is in the better half of the industry: LGND outperforms 77.49% of its industry peers.
  • A Debt/Equity ratio of 0.47 indicates that LGND is not too dependend on debt financing.
  • LGND has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: LGND underperforms 61.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Altman-Z 5.82
ROIC/WACC0.17
WACC9.54%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 24.69 indicates that LGND has no problem at all paying its short term obligations.
  • LGND's Current ratio of 24.69 is amongst the best of the industry. LGND outperforms 93.72% of its industry peers.
  • A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
  • LGND has a Quick ratio of 24.30. This is amongst the best in the industry. LGND outperforms 92.67% of its industry peers.
Industry RankSector Rank
Current Ratio 24.69
Quick Ratio 24.3
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.26% over the past year.
  • The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
  • LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.83%.
  • LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • LGND is valuated quite expensively with a Price/Earnings ratio of 27.21.
  • LGND's Price/Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 78.53% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 28.25. LGND is around the same levels.
  • LGND is valuated rather expensively with a Price/Forward Earnings ratio of 23.45.
  • 76.44% of the companies in the same industry are more expensive than LGND, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 27.50. LGND is around the same levels.
Industry RankSector Rank
PE 27.21
Fwd PE 23.45
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 78.01% of the companies are valued more expensively.
  • LGND's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. LGND is cheaper than 74.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 126.89
EV/EBITDA 50.12
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LGND has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as LGND's earnings are expected to grow with 19.77% in the coming years.
PEG (NY)0.77
PEG (5Y)2.02
EPS Next 2Y21.72%
EPS Next 3Y19.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LGND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIGAND PHARMACEUTICALS

NASDAQ:LGND (2/4/2026, 8:00:03 PM)

Premarket: 197.36 -0.97 (-0.49%)

198.33

-0.51 (-0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners106.73%
Inst Owner Change-0.56%
Ins Owners1.62%
Ins Owner Change-1.26%
Market Cap3.90B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (25.2%)
Short Float %6.59%
Short Ratio5.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)32.94%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-23.57%
EPS NY rev (1m)3.65%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0.65%
Revenue NQ rev (3m)-10.47%
Revenue NY rev (1m)-3.37%
Revenue NY rev (3m)12.73%
Valuation
Industry RankSector Rank
PE 27.21
Fwd PE 23.45
P/S 15.54
P/FCF 126.89
P/OCF 122.3
P/B 4.11
P/tB 9.55
EV/EBITDA 50.12
EPS(TTM)7.29
EY3.68%
EPS(NY)8.46
Fwd EY4.27%
FCF(TTM)1.56
FCFY0.79%
OCF(TTM)1.62
OCFY0.82%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.77
PEG (5Y)2.02
Graham Number88.99
Profitability
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROCE 1.99%
ROIC 1.58%
ROICexc 2.92%
ROICexgc 9.48%
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
FCFM 12.24%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Debt/EBITDA 7.07
Cap/Depr 3.38%
Cap/Sales 0.46%
Interest Coverage 96.15
Cash Conversion 50.63%
Profit Quality 63.32%
Current Ratio 24.69
Quick Ratio 24.3
Altman-Z 5.82
F-Score5
WACC9.54%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A

LIGAND PHARMACEUTICALS / LGND FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 6 / 10 to LGND.


What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


How profitable is LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.


What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.